CaseBioscience Joins $7.3 Million ARPA-H Project for Cell Therapy Preservation

CaseBioscience Participates in Groundbreaking Project

In a significant development for the field of biotechnology, CaseBioscience® has announced its participation in a pivotal multidisciplinary team led by Likarda, which has secured a funding of up to $7.3 million from the Advanced Research Projects Agency for Health (ARPA-H). This financial backing is allocated for innovative research focused on the preservation of cell therapies at ambient temperatures.

The Advanced Research Projects Agency for Health, commonly known as ARPA-H, aims to support revolutionary technologies that facilitate the production, storage, and shipping of live cell products without the need for traditional refrigeration methods. The initiative, under the BioStabilization Systems (BoSS) program, seeks to make cutting-edge biologic medicines as easy to handle as commercial over-the-counter products like aspirin.

The Need for Ambient Preservation

Currently, many cell-based therapies, noted for their potential to transform treatments for diseases such as cancer, face significant distribution challenges due to their stringent storage requirements. These therapies often necessitate carefully controlled environments to maintain cellular viability and functionality, complicating their transport logistics.

Dr. John Baust, a key figure in the biopreservation field involved with the project, highlighted historical research challenges in stabilizing live cells, particularly emphasizing that significant scientific barriers have hindered progress for over two decades. The ARPA-H BoSS initiative presents a unique opportunity to collectively tackle these challenges through interdisciplinary collaboration, encompassing various scientific and technical perspectives.

Structure of the Project

The project features a team known as the Reversible Ambient Biostabilization (RAB) team, one of the select few chosen to receive funding under the BoSS program. Along with CaseBioscience and Likarda, this team comprises various other distinguished entities, including Draper, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and the Spencer Laboratory from the University of Colorado Boulder.

Kickstarting the project is a 15-month initial phase, which commenced on September 24, 2026. The RAB team is set to focus on integrating specialized physiological mechanisms, innovative cellular protection strategies, and bioengineering approaches aimed at developing methods for the ambient storage and transportation of living cell therapies.

Expert Contributions

CaseBioscience will leverage its expertise in clinical culture media formulation, biopreservation, and cellular metabolism to further advance and evaluate groundbreaking methods for long-term stabilization of these therapies without refrigeration. Dr. Lynda McGinnis, the company’s director of research and development, emphasized that this undertaking revisits research initiatives started in Boston two decades ago, signaling a rapidly evolving landscape in the domain of clinical treatment storage methods.

Adding to the excitement, Dr. Kevin Flynn, CaseBioscience’s Chief Scientific Officer, expressed the team’s enthusiasm over the collaborative potential of this project. He articulated that with robust scientific knowledge and sufficient resources, groundbreaking advancements in ambient preservation could soon transition from concept to reality, bridging the gap toward wide accessibility of cell-based therapies.

Ami Mezezi, co-founder and CEO of CaseBioscience, expressed pride in the company’s selection by ARPA-H for this prestigious program, stating that this recognition affirms their scientific contributions, preservation technology, and the collaborative effort driving this innovative endeavor.

Conclusion

The launch of the BoSS program symbolizes a transformative opportunity in biotechnology and opens avenues for enhancing patient access to innovative treatments. With CaseBioscience's notable participation bolstered by leading scientific minds and institutions, the ambitious goal to simplify the logistics surrounding living cell therapies is now within reach, potentially altering the future of medical treatments significantly. Efforts like these not only represent a step forward in therapeutic delivery but also promise a brighter future for patients requiring these cutting-edge solutions.